SEC reporting owner

Dexcel Pharma Technologies Ltd. SEC insider disclosures

Explore Dexcel Pharma Technologies Ltd.'s reporting-owner identity, issuer relationships, purchases, sales and SEC filing receipts.

As of 2026-10-07T00:29:11.873Z

Reporting owner CIK
0001720007
Issuers
7
Coverage
verified

Issuer relationships

A reporting-owner CIK identifies the filer across issuer relationships and name aliases. A filer may be an individual or an organization; the filing role is the relevant evidence.

Arbutus Biopharma Corp0001447028ABUSNoNo
Myovant Sciences Ltd.0001679082MYOVNoNo
Axovant Gene Therapies Ltd.0001636050AXONNoNo
Urovant Sciences Ltd.0001740547UROVNoNo
Intec Pharma Ltd.0001638381NTECNoNo
Protalix BioTherapeutics, Inc.0001006281PLXNoNo
Roivant Sciences Ltd.0001635088ROIVNoNo

Recent SEC transactions

Code P identifies a purchase, S a sale and A an award. Awards and open-market purchases describe different events. Use the public availability date when deciding when a researcher could have known about the transaction.

No records are available for this view.

Up to 50 transactions from the recent two-year owner window.

Source evidence and strategy eligibility

The transactions below come from filings; a historical tracker separately simulates following eligible events. Joint filers can report the same transaction, and an owner can have filings at multiple companies. Public availability, amendment lineage and verified coverage determine which events a historical tracker may use.

The current directory marks this owner's filing coverage verified.